Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Extends Offer for Dionex

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said after the close of the market Tuesday that it has extended until midnight, New York City time, on April 7, its tender offer to acquire all of the outstanding shares of Dionex.

Thermo Fisher inked the deal in December to acquire Dionex for $118.50 per share in cash for a total transaction value of $2.1 billion. The tender offer represented a 21 percent premium to Dionex's closing share price of $98.17 on Dec. 10, the last trading day prior to the announcement.

As of 5:00 pm, New York City time, on Feb. 15, approximately 9.1 million shares of Dionex's common stock, representing around 52 percent of all outstanding shares, had been tendered and not withdrawn from the offer.

The deal already has cleared US antitrust review, and Thermo Fisher expects to close the deal early in the second quarter, it said yesterday.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.